Skip to content

Author

Ichidai Tanaka

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Paraneoplastic Neurological Syndrome in a Patient with Limited-stage Small-cell Lung Cancer Receiving Durvalumab Maintenance after Concurrent Chemoradiotherapy: A Case Report.

Paraneoplastic neurological syndromes (PNSs) are immune-mediated disorders associated with small-cell lung cancer (SCLC). Durvalumab following concurrent chemoradiotherapy (cCRT) improves outcomes in patients with limited-stage SCLC (LS-SCLC); however, its safety in patients with pre-existing PNS and residual neurologi...

Daisuke Abe, R. Matsuzawa, Tomoki Hirunagi et al. · 0 citations
Open access Sep 2026

Long-Term Benefit With First-Line Osimertinib Monotherapy in EGFR-Mutated Advanced NSCLC in the Era of Intensified First-Line Therapy.

INTRODUCTION First-line osimertinib monotherapy remains a standard treatment for advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), although intensified regimens improve outcomes at the cost of an increased toxicity and treatment burden. We characterized pretreatment clinical f...

Masaki Ishida, T. Yamada, O. Yamaguchi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.